This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play
by Kinjel Shah
J&J has been trading above its 50- and 200-day SMAs for six months as strong 2025 execution, new drugs and pipeline progress support bullish momentum.
pharmaceuticals
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
by Ahan Chakraborty
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
biotechnology biotechs medical pharmaceuticals
Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up
by Zacks Equity Research
CYTK enters a new era as FDA approval of Myqorzo transforms it into a commercial biotech, opening a long-term growth runway in cardiology.
biotechnology biotechs medical pharmaceuticals
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
by Sundeep Ganoria
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
biotechs medical pharmaceuticals
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026
by Ekta Bagri
EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well.
biotechnology biotechs medical pharmaceuticals
Top Research Reports for NVIDIA, Netflix & Merck
by Mark Vickery
New research highlights NVIDIA's AI-driven growth, Netflix's ad-tier momentum and Merck's pipeline progress, while microcaps also make the cut.
construction consumer-discretionary medical pharmaceuticals semiconductor
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates
by Zacks Equity Research
VTRS scores four regulatory wins in 2025, from FDA approval of a generic Sandostatin LAR to NDA and IND clearances across its pipeline.
biotechnology medical pharmaceuticals
Pharma's $370B Bet on America: The ETF Plays for 2026
by Aparajita Dutta
Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.
etfs pharmaceuticals
Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock
by Kinjel Shah
Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.
pharmaceuticals
Can Merck Successfully Steer Through the Upcoming Headwinds?
by Kanishka Das
MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.
pharmaceuticals